FR3058060B1 - Composition pharmaceutique comprenant le beta-elemene, le lupeol, le cinnamaldehyde et/ou le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine. - Google Patents

Composition pharmaceutique comprenant le beta-elemene, le lupeol, le cinnamaldehyde et/ou le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine. Download PDF

Info

Publication number
FR3058060B1
FR3058060B1 FR1771115A FR1771115A FR3058060B1 FR 3058060 B1 FR3058060 B1 FR 3058060B1 FR 1771115 A FR1771115 A FR 1771115A FR 1771115 A FR1771115 A FR 1771115A FR 3058060 B1 FR3058060 B1 FR 3058060B1
Authority
FR
France
Prior art keywords
beta
benzoyloxycinnalmaldehyde
hydroxycinnamaldehyde
lupeol
elemene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1771115A
Other languages
English (en)
Other versions
FR3058060A1 (fr
Inventor
Guy Faustin Monkam Nitcheu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1670645A external-priority patent/FR3058058A1/fr
Application filed by Individual filed Critical Individual
Priority to PCT/IB2017/056612 priority Critical patent/WO2018078539A1/fr
Priority to EP17808579.1A priority patent/EP3429568A1/fr
Priority to KR1020197015106A priority patent/KR20190077449A/ko
Priority to MA044413A priority patent/MA44413A/fr
Priority to CA3043456A priority patent/CA3043456A1/fr
Priority to MX2019003685A priority patent/MX2019003685A/es
Priority to CN201780049274.1A priority patent/CN109562080B/zh
Publication of FR3058060A1 publication Critical patent/FR3058060A1/fr
Priority to ZA2019/02910A priority patent/ZA201902910B/en
Priority to IL266623A priority patent/IL266623A/en
Publication of FR3058060B1 publication Critical patent/FR3058060B1/fr
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique, caractérisée en ce qu'elle comprend en tant que principe actif, une combinaison de béta-élémène, de lupéol et d'un agent pharmaceuticalement actif choisi parmi le cinnamaldéhyde, le 2-hydroxycinnamaldéhyde , le 2'- benzoyloxycinnalmaldéhyde, le béta-sitostérol, la curcumine et leurs mélanges.
FR1771115A 2016-10-31 2017-10-23 Composition pharmaceutique comprenant le beta-elemene, le lupeol, le cinnamaldehyde et/ou le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine. Active FR3058060B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MX2019003685A MX2019003685A (es) 2016-10-31 2017-10-25 Composicion farmaceutica para uso en el tratamiento terapeutico del cancer y complicaciones del cancer.
CN201780049274.1A CN109562080B (zh) 2016-10-31 2017-10-25 用于治疗癌症和癌症并发症的药物组合物
EP17808579.1A EP3429568A1 (fr) 2016-10-31 2017-10-25 Composition pharmaceutique utilisée pour le traitement thérapeutique du cancer et ses complications
KR1020197015106A KR20190077449A (ko) 2016-10-31 2017-10-25 암 및 암 합병증의 치료학적 처치에 사용하기 위한 약제학적 조성물
MA044413A MA44413A (fr) 2016-10-31 2017-10-25 Composition pharmaceutique utilisée pour le traitement thérapeutique du cancer et ses complications
CA3043456A CA3043456A1 (fr) 2016-10-31 2017-10-25 Composition pharmaceutique utilisee pour le traitement therapeutique du cancer et ses complications
PCT/IB2017/056612 WO2018078539A1 (fr) 2016-10-31 2017-10-25 Composition pharmaceutique utilisée pour le traitement thérapeutique du cancer et ses complications
ZA2019/02910A ZA201902910B (en) 2016-10-31 2019-05-09 Pharmaceutical composition for use in the therapeutic treatment of cancer and complications of cancer
IL266623A IL266623A (en) 2016-10-31 2019-05-14 A pharmaceutical preparation for use in the therapeutic treatment of cancer and complications of cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR1670645A FR3058058A1 (fr) 2016-10-31 2016-10-31 Composition pharmaceutique comprenant en tant que principe actif une combinaison de beta-elemene, de lupeol et du 2-hydroxycinnamaldehyde et/ou du 2-benzoyloxycinnalmaldehyde et/ou beta-sitosterol
FR1670645 2016-10-31
FR1670666A FR3058059B1 (fr) 2016-10-31 2016-11-08 Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
FR1670666 2016-11-08

Publications (2)

Publication Number Publication Date
FR3058060A1 FR3058060A1 (fr) 2018-05-04
FR3058060B1 true FR3058060B1 (fr) 2020-07-17

Family

ID=61979159

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1771115A Active FR3058060B1 (fr) 2016-10-31 2017-10-23 Composition pharmaceutique comprenant le beta-elemene, le lupeol, le cinnamaldehyde et/ou le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.

Country Status (1)

Country Link
FR (1) FR3058060B1 (fr)

Also Published As

Publication number Publication date
FR3058060A1 (fr) 2018-05-04

Similar Documents

Publication Publication Date Title
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
CL2018002703A1 (es) Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr). (divisional solicitud 201401291)
DOP2019000117A (es) Nuevos derivados de quinolina
CO2019001043A2 (es) Composición de cannabis
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
BR112014009031A2 (pt) formulações de etanercept estabilizadas com íons de metais
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
EA201990820A1 (ru) Способы лечения митохондриальных и метаболических нарушений
UY37789A (es) Nuevos derivados de azaquinolina
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
BR112018005861A2 (pt) derivados de ácido oleanólico modificado com c4 para a inibição de il-17 e outros usos
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112015017246A2 (pt) formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel
CR20150505A (es) Derivado de dihidropiridazin-3,5-diona
UY37705A (es) Nuevos derivados de pirazol bicíclicos
NZ735777A (en) Methods and compositions to inhibit symptoms associated with veisalgia
ECSP20023626A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
MA40937A (fr) Acide benzoïque, dérivés d'acide benzoïque et conjugués d'acide hétéroarylcarboxylique d'oxymorphone, promédicaments, leurs procédés de fabrication et d'utilisation
AR101901A1 (es) Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod
MA45718A (fr) Combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1, utilisations et compositions pharmaceutiques associées
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer
FR3058060B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol, le cinnamaldehyde et/ou le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.

Legal Events

Date Code Title Description
PLSC Publication of the preliminary search report

Effective date: 20180817

PLFP Fee payment

Year of fee payment: 2

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7